ERBB2 and ovarian cancer: Specifically, LIG1 is an attractive target for personalization of ovarian cancer therapy (Ali et al., 2021), and decreased eEF2 phosphorylation, mediated by increased PP2A activity, contributes to resistance to HER2 inhibition (McDermott et al., 2014).